Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04182516 · ClinicalTrials.gov registry record · Phase 1
Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors
A Phase 1 study, sponsored by Nerviano Medical Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT04182516 is a Phase 1 study that was terminated before completion, run by Nerviano Medical Sciences. The registered enrollment target is 52 participants.
The verdict
NCT04182516, a Phase 1 study, was terminated before completion, sponsored by Nerviano Medical Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
Phase I, first-in-human, open-label, multicenter, dose-escalation and dose expansion study with the aim of exploring safety, tolerability and preliminary antitumor activity of NMS-03305293 (a PARP inhibitor) as single agent in adult patients with selected advanced/metastatic, relapsed/refractory solid tumors who have exhausted standard treatment options or for whom standard therapy is considered unsuitable.
Interventions
- DRUG NMS-03305293
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2019-11-25 |
| Est. Completion | 2024-05-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04182516
The ClinicalTrials.gov registry entry for NCT04182516 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nerviano Medical Sciences, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NMS-03305293 is the first listed.
NCT04182516 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04182516 about?
NCT04182516 is a clinical study titled "Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors". Phase I, first-in-human, open-label, multicenter, dose-escalation and dose expansion study with the aim of exploring safety, tolerability and preliminary antitumor activity of NMS-03305293 (a PARP inhibitor) as single agent in adult patients with selected advanced/metastatic, relapsed/refractory sol...
What is the current status of trial NCT04182516?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2019-11-25. Estimated completion is 2024-05-16.
What interventions are being tested in trial NCT04182516?
The interventions under investigation include: NMS-03305293 (DRUG).
Who is sponsoring clinical trial NCT04182516?
This trial is sponsored by Nerviano Medical Sciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.